BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. Expert Opin Investig Drugs 2020;29:595-602. [PMID: 32412796 DOI: 10.1080/13543784.2020.1764534] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106550] [Reference Citation Analysis]
2 Nowell J, Blunt E, Edison P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease. Mol Psychiatry 2022. [PMID: 36258018 DOI: 10.1038/s41380-022-01792-4] [Reference Citation Analysis]
3 Lee W. Development of neurodegenerative disorders and the role of gut. J Geriatr Neurol 2022;1:53-58. [DOI: 10.53991/jgn.2022.00108] [Reference Citation Analysis]
4 Naren P, Cholkar A, Kamble S, Samim KS, Srivastava S, Madan J, Mehra N, Tiwari V, Singh SB, Khatri DK. Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay. JAD 2022. [DOI: 10.3233/jad-220682] [Reference Citation Analysis]
5 Sun X, Xue L, Wang Z, Xie A. Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism. Front Neurosci 2022;16:878239. [PMID: 35873830 DOI: 10.3389/fnins.2022.878239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Vidović M, Rikalovic MG. Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches. Cells 2022;11:1732. [PMID: 35681426 DOI: 10.3390/cells11111732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease. Expert Opin Ther Targets 2022. [PMID: 35584372 DOI: 10.1080/14728222.2022.2079492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Arbo BD, Schimith LE, Goulart dos Santos M, Hort MA. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174800] [Reference Citation Analysis]
9 Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci 2022;23:739. [PMID: 35054924 DOI: 10.3390/ijms23020739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
10 Cao B, Zhang Y, Chen J, Wu P, Dong Y, Wang Y. Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease. Metab Brain Dis 2021. [PMID: 34817756 DOI: 10.1007/s11011-021-00879-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
11 Lamontagne-Proulx J, Coulombe K, Dahhani F, Côté M, Guyaz C, Tremblay C, Di Marzo V, Flamand N, Calon F, Soulet D. Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model. Nutrients 2021;13:4218. [PMID: 34959768 DOI: 10.3390/nu13124218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Li Y, Glotfelty EJ, Karlsson T, Fortuno LV, Harvey BK, Greig NH. The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. J Neurochem 2021. [PMID: 34569615 DOI: 10.1111/jnc.15521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Manfready RA, Engen PA, Verhagen Metman L, Sanzo G, Goetz CG, Hall DA, Forsyth CB, Raeisi S, Voigt RM, Keshavarzian A. Attenuated Postprandial GLP-1 Response in Parkinson's Disease. Front Neurosci 2021;15:660942. [PMID: 34276285 DOI: 10.3389/fnins.2021.660942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mortada I, Farah R, Nabha S, Ojcius DM, Fares Y, Almawi WY, Sadier NS. Immunotherapies for Neurodegenerative Diseases. Front Neurol 2021;12:654739. [PMID: 34163421 DOI: 10.3389/fneur.2021.654739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
15 Graham DL, Madkour HS, Noble BL, Schatschneider C, Stanwood GD. Long-term functional alterations following prenatal GLP-1R activation. Neurotoxicol Teratol 2021;87:106984. [PMID: 33864929 DOI: 10.1016/j.ntt.2021.106984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Esparza-Salazar FJ, Lezama-Toledo AR, Rivera-Monroy G, Borlongan CV. Exendin-4 for Parkinson's disease. Brain Circ 2021;7:41-3. [PMID: 34084977 DOI: 10.4103/bc.bc_21_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Girges C, Vijiaratnam N, Athauda D, Auld G, Gandhi S, Foltynie T. The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs Aging 2021;38:355-73. [PMID: 33738783 DOI: 10.1007/s40266-021-00853-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci 2021;4:858-69. [PMID: 33860208 DOI: 10.1021/acsptsci.1c00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Takaku S, Tsukamoto M, Niimi N, Yako H, Sango K. Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro. Int J Mol Sci 2021;22:2971. [PMID: 33804063 DOI: 10.3390/ijms22062971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
20 Yu SJ, Chen S, Yang YY, Glotfelty EJ, Jung J, Kim HK, Choi HI, Choi DS, Hoffer BJ, Greig NH, Wang Y. PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. Front Neurosci 2020;14:785. [PMID: 32848559 DOI: 10.3389/fnins.2020.00785] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]